{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:27:34Z","timestamp":1761060454101,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T00:00:00Z","timestamp":1510617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00277-017-3175-7","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T06:10:44Z","timestamp":1510639844000},"page":"289-297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Delayed recovery of serum immunoglobulin G is a poor prognostic marker in patients with follicular lymphoma treated with rituximab maintenance"],"prefix":"10.1007","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9806-5077","authenticated-orcid":false,"given":"Yoshiharu","family":"Kusano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihito","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Tsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Terui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohiko","family":"Hatake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"issue":"2","key":"3175_CR1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2):435\u2013445","journal-title":"Blood"},{"issue":"suppl 2","key":"3175_CR2","first-page":"29","volume":"2\u20139","author":"DG Maloney","year":"2002","unstructured":"Maloney DG, Smith B, Rose A (2002) Rituximab: mechanism of action and resistance. Semin Oncol 2\u20139(suppl 2):29","journal-title":"Semin Oncol"},{"issue":"5","key":"3175_CR3","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","volume":"91","author":"D Shan","year":"1998","unstructured":"Shan D, Ledbetter JA, Press OW (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91(5):1644\u20131652","journal-title":"Blood"},{"issue":"10","key":"3175_CR4","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","volume":"27","author":"H Hochster","year":"2009","unstructured":"Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ (2009) Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 27(10):1607\u20131614. https:\/\/doi.org\/10.1200\/JCO.2008.17.1561","journal-title":"J Clin Oncol"},{"issue":"20","key":"3175_CR5","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","volume":"20","author":"JD Hainsworth","year":"2002","unstructured":"Hainsworth JD, Litchy S, Burris HA et al (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 20(20):4261\u20134267. https:\/\/doi.org\/10.1200\/JCO.2002.08.674","journal-title":"J Clin Oncol"},{"issue":"12","key":"3175_CR6","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly 4 schedule. Blood 103(12):4416\u20134423. https:\/\/doi.org\/10.1182\/blood-2003-10-3411","journal-title":"Blood"},{"issue":"17","key":"3175_CR7","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH Oers van","year":"2010","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L et al (2010) Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28(17):2853\u20132858. https:\/\/doi.org\/10.1200\/JCO.2009.26.5827","journal-title":"J Clin Oncol"},{"key":"3175_CR8","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.V116.21.1802.1802","volume":"116","author":"CJ Taverna","year":"2010","unstructured":"Taverna CJ, Bassi S, Hitz F et al (2010) Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: Safety analysis of the randomized phase III trial SAKK 35\/03. Blood 116:1802 1802 (abstract 1802)","journal-title":"Blood"},{"issue":"9759","key":"3175_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2010","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Ferm\u00e9 C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H (2010) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(10)62175-7","journal-title":"Lancet"},{"issue":"6","key":"3175_CR10","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","volume":"100","author":"LE Kolk van der","year":"2002","unstructured":"van der Kolk LE, Baars JW, Prins MH, van Oers MH (2002) Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100(6):2257\u20132259","journal-title":"Blood"},{"issue":"3","key":"3175_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","volume":"8","author":"MK Slifka","year":"1998","unstructured":"Slifka MK, Antia R, Whitmire JK, Ahmed R (1998) Humoral immunity due to long-lived plasma cells. Immunity 8(3):363\u2013372. https:\/\/doi.org\/10.1016\/S1074-7613(00)80541-5","journal-title":"Immunity"},{"issue":"1","key":"3175_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","volume":"149","author":"N Cooper","year":"2010","unstructured":"Cooper N, Arnold DM (2010) The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune in the treatment of autoimmune disease. Br J Harmatol 149(1):3\u201313. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08076.x","journal-title":"Br J Harmatol"},{"issue":"9","key":"3175_CR13","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/annonc\/mdl141","volume":"17","author":"F Cavanillas","year":"2006","unstructured":"Cavanillas F, Liboy I, Pavia O et al (2006) High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 17(9):1424\u20131427. https:\/\/doi.org\/10.1093\/annonc\/mdl141","journal-title":"Ann Oncol"},{"issue":"2","key":"3175_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","volume":"13","author":"C Casulo","year":"2013","unstructured":"Casulo C, Maragulia J, Zelenetz AD (2013) Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 13(2):106\u2013111. https:\/\/doi.org\/10.1016\/j.clml.2012.11.011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"3175_CR15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1517\/14740338.4.3.599","volume":"4","author":"Y Tsutsumi","year":"2005","unstructured":"Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N (2005) Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 4(3):599\u2013608. https:\/\/doi.org\/10.1517\/14740338.4.3.599","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"3175_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1600-0609.2006.00693.x","volume":"77","author":"M Nishio","year":"2006","unstructured":"Nishio M, Fujimoto K, Yamamoto S, Endo T, Sakai T, Obara M, Kumano K, Minauchi K, Yamaguchi K, Takeda Y, Sato N, Koizumi K, Mukai M, Koike T (2006) Hypogammaglobulinemia with delayed recovery in memory B cells and an impaired isotype expression after expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur J Haematol 77(3):226\u2013232. https:\/\/doi.org\/10.1111\/j.1600-0609.2006.00693.x","journal-title":"Eur J Haematol"},{"issue":"3","key":"3175_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s12185-010-0528-6","volume":"91","author":"E Irie","year":"2010","unstructured":"Irie E, Shirota Y, Suzuki C, Tajima Y, Ishizawa K, Kameoka J, Harigae H, Ishii T (2010) Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol 91(3):501\u2013508. https:\/\/doi.org\/10.1007\/s12185-010-0528-6","journal-title":"Int J Hematol"},{"issue":"1","key":"3175_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1365-2141.2009.07715.x","volume":"146","author":"N Cooper","year":"2009","unstructured":"Cooper N, Davies EG, Thrasher AJ (2009) Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol 146(1):120\u2013122. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07715.x","journal-title":"Br J Haematol"},{"issue":"10","key":"3175_CR19","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.autrev.2014.08.036","volume":"13","author":"R Levy","year":"2014","unstructured":"Levy R, Mah\u00e9vas M, Galicier L, Boutboul D, Moroch J, Loustau V, Guillaud C, Languille L, Fain O, Bierling P, Khellaf M, Michel M, Oksenhendler E, Godeau B (2014) Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature. Autoimmun Rev 13(10):1055\u20131063. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.036","journal-title":"Autoimmun Rev"},{"issue":"25","key":"3175_CR20","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1056\/NEJMra072739","volume":"358","author":"OJ Finn","year":"2008","unstructured":"Finn OJ (2008) Cancer immunology. N Engl J Med 358(25):2704\u20132715. https:\/\/doi.org\/10.1056\/NEJMra072739","journal-title":"N Engl J Med"},{"issue":"1","key":"3175_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbcan.2007.07.003","volume":"1776","author":"M Rescigno","year":"2007","unstructured":"Rescigno M, Avogadri F, Curigliano G (2007) Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta 1776(1):108\u2013123. https:\/\/doi.org\/10.1016\/j.bbcan.2007.07.003","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"3175_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3):309\u2013322. https:\/\/doi.org\/10.1016\/j.ccr.2012.02.022","journal-title":"Cancer Cell"},{"issue":"10","key":"3175_CR23","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00262-009-0733-4","volume":"58","author":"M Reuschenbach","year":"2009","unstructured":"Reuschenbach M, von Knebel Doeberitz M, Wentzensen N (2009) A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 58(10):1535\u20131544. https:\/\/doi.org\/10.1007\/s00262-009-0733-4","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"3175_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.blre.2008.09.001","volume":"23","author":"R Houot","year":"2009","unstructured":"Houot R, Levy R (2009) Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev 23(3):137\u2013142. https:\/\/doi.org\/10.1016\/j.blre.2008.09.001","journal-title":"Blood Rev"},{"issue":"6","key":"3175_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.coi.2011.10.007","volume":"23","author":"S Pillai","year":"2011","unstructured":"Pillai S, Mattoo H, Cariappa A (2011) B cells and autoimmunity. Curr Opin Immunol 23(6):721\u2013731. https:\/\/doi.org\/10.1016\/j.coi.2011.10.007","journal-title":"Curr Opin Immunol"},{"key":"3175_CR26","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon. IARC Press, Lyon"},{"issue":"5","key":"3175_CR27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"issue":"4","key":"3175_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large- B-cell lymphoma. N Engl J Med 346(4):235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"issue":"18","key":"3175_CR29","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/jco.2007.25.18_suppl.8004","volume":"25","author":"HS Hochster","year":"2007","unstructured":"Hochster HS, Weller E, Gascoyne R et al (2007) Cyclophosphamide\/fludarabine (CF) in advanced indolent lymphoma: results from the E1496 Trial. J Clin Oncol 25(18):8004 8004 (abstract 8004)","journal-title":"J Clin Oncol"},{"issue":"3","key":"3175_CR30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"3175_CR31","doi-asserted-by":"crossref","first-page":"AB10","DOI":"10.1016\/j.jaci.2013.12.059","volume":"44","author":"H Lu","year":"2014","unstructured":"Lu H, Pundole X (2014) Factors predicting long-term hypogammaglobulinemia in lymphoma survivors. J Allergy Clin Imunol 44(2):AB10","journal-title":"J Allergy Clin Imunol"},{"issue":"36","key":"3175_CR32","doi-asserted-by":"publisher","first-page":"14526","DOI":"10.1073\/pnas.1211018109","volume":"109","author":"PP Ng","year":"2012","unstructured":"Ng PP, Jia M, Patel KG, Brody JD, Swartz JR, Levy S, Levy R (2012) A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity. Proc Natl Acad Sci U S A 109(36):14526\u201314531. https:\/\/doi.org\/10.1073\/pnas.1211018109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"3175_CR33","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1200\/JCO.2004.06.003","volume":"22","author":"WK Weng","year":"2004","unstructured":"Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R (2004) Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 22(23):4717\u20134724. https:\/\/doi.org\/10.1200\/JCO.2004.06.003","journal-title":"J Clin Oncol"},{"issue":"17","key":"3175_CR34","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJM199210223271705","volume":"327","author":"LW Kwak","year":"1992","unstructured":"Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R (1992) Induction of immune responses in patients with B-cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. New Engl J Med 327(17):1209\u20131215. https:\/\/doi.org\/10.1056\/NEJM199210223271705","journal-title":"New Engl J Med"},{"issue":"10","key":"3175_CR35","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/13928","volume":"5","author":"M Bendandi","year":"1999","unstructured":"Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony stimulating factor against lymphoma. Nat Med 5(10):1171\u20131177. https:\/\/doi.org\/10.1038\/13928","journal-title":"Nat Med"},{"issue":"1","key":"3175_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nm0196-52","volume":"2","author":"FJ Hsu","year":"1996","unstructured":"Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2(1):52\u201358. https:\/\/doi.org\/10.1038\/nm0196-52","journal-title":"Nat Med"},{"issue":"9","key":"3175_CR37","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V89.9.3129","volume":"89","author":"FJ Hsu","year":"1997","unstructured":"Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma\u2014long-term results of a clinical trial. Blood 89(9):3129\u20133135","journal-title":"Blood"},{"issue":"5","key":"3175_CR38","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","volume":"99","author":"JM Timmerman","year":"2002","unstructured":"Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99(5):1517\u20131526. https:\/\/doi.org\/10.1182\/blood.V99.5.1517","journal-title":"Blood"},{"key":"3175_CR39","doi-asserted-by":"crossref","unstructured":"Levy R, Robertson MJ, Ganjoo K, et al. Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to nonspecific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin\u2019s lymphoma (fNHL). AACR meeting; 2008 Abstract LB-204","DOI":"10.1158\/1538-7445.AM2008-LB-204"},{"key":"3175_CR40","doi-asserted-by":"crossref","unstructured":"Ai WZ, Tibshirani R, Taidi B et al (2009) Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood 113:5743\u20135746","DOI":"10.1182\/blood-2009-01-201988"},{"issue":"8","key":"3175_CR41","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1158\/0008-5472.CAN-05-4233","volume":"66","author":"C Bertinetti","year":"2006","unstructured":"Bertinetti C, Zirlik K, Heining-Mikesch K, Ihorst G, Dierbach H, Waller CF, Veelken H (2006) Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res 66(8):4496\u20134502. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4233","journal-title":"Cancer Res"},{"issue":"19","key":"3175_CR42","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1200\/JCO.2005.04.4289","volume":"24","author":"CH Redfern","year":"2006","unstructured":"Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF (2006) Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin\u2019s lymphoma resulting in durable clinical responses. J Clin Oncol 24(19):3107\u20133112. https:\/\/doi.org\/10.1200\/JCO.2005.04.4289","journal-title":"J Clin Oncol"},{"key":"3175_CR43","doi-asserted-by":"crossref","unstructured":"Flinn I, Van der Jagt R, Chang JE et al (2017) First-line treatment of iNHL or MCL patients with BR or R-CHOP\/R-CVP: Results of the BRIGHT 5-year follow-up study. J Clin Oncol 35(15 suppl):7500\u20137500","DOI":"10.1002\/hon.2437_130"},{"key":"3175_CR44","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Maschmeyer G, Ganser A et al (2017) Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study. J Clin Oncol 35(15 suppl):7501\u20137501","DOI":"10.1200\/JCO.2017.35.15_suppl.7501"},{"issue":"5","key":"3175_CR45","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Ha\u00efoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258\u20131265. https:\/\/doi.org\/10.1182\/blood-2003-12-4434","journal-title":"Blood"},{"issue":"27","key":"3175_CR46","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-C\u00e9ligny P (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555\u20134562. https:\/\/doi.org\/10.1200\/JCO.2008.21.3991","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3175-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3175-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3175-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T19:59:00Z","timestamp":1603310340000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3175-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3175"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3175-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2017,11,14]]}}}